Sunitha Vege

Sunitha Vege

Auto-generated profile, based on publicly available information

Sunitha Vege

Immunohematology and Genomics Laboratory New York Blood Center New York New York USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
AJAbigail Joseph
Abigail Joseph
CMCody J. Murray
Cody J. Murray
NNNatasha D. Novikov
Natasha D. Novikov
RVRandall W. Velliquette
Randall W. Velliquette
SVSunitha Vege
Sunitha Vege
WLWilliam J. Lane
William J. Lane
ABO compatibility is important for kidney transplantation, with longer waitlist times for blood group B kidney transplant candidates. However, kidneys from non-A1 (eg, A2) subtype donors, which express less A antigen, can be safely transplanted into group B recipients. ABO subtyping is routinely performed using anti-A1 lectin, but DNA-based genotyping is also possible. Here, we compare lectin and genotyping testing. Lectin and genotype subtyping was performed on 554 group A deceased donor samples at 2 transplant laboratories. The findings were supported by 2 additional data sets of 210 group A living kidney donors and 124 samples with unclear lectin testing sent to a reference laboratory. In deceased donors, genotyping found 65% more A2 donors than lectin testing, most with weak lectin reactivity, a finding supported in living donors and samples sent for reference testing. DNA sequencing and flow cytometry showed that the discordances were because of several factors, including transfusion, small variability in A antigen levels, and rare ABO∗A2.06 and ABO∗A2.16 sequences. Although lectin testing is the current standard for transplantation subtyping, genotyping is accurate and could increase A2 kidney transplant opportunities for group B candidates, a difference that should reduce group B wait times and improve transplant equity.

30 January 2024 in Transfusion
Verified
Journal Article
Closed access
NINarek Israelyan
Narek Israelyan
SVSunitha Vege
Sunitha Vege
DFDavid F. Friedman
David F. Friedman
ZZZhe Zhang
Zhe Zhang
SUStacey Uter
Stacey Uter
SCStella T. Chou
Stella T. Chou

1 April 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
KTKaoru Takasaki
Kaoru Takasaki
DFDavid F. Friedman
David F. Friedman
SUStacey Uter
Stacey Uter
SVSunitha Vege
Sunitha Vege
CWConnie M. Westhoff
Connie M. Westhoff
SCStella T. Chou
Stella T. Chou

25 September 2020 in Transfusion
Verified
Journal Article
Closed access
PDF file
SVSunitha Vege
Sunitha Vege
USUlrik Sprogøe
Ulrik Sprogøe
CLChristine Lomas‐Francis
Christine Lomas‐Francis
MJMarianne A. Jakobsen
Marianne A. Jakobsen
BABerit Antonsen
Berit Antonsen
CWConnie M. Westhoff
Connie M. Westhoff

30 April 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
LGLohith Gowda
Lohith Gowda
SVSunitha Vege
Sunitha Vege
DKDebra Kessler
Debra Kessler
BSBeth Shaz
Beth Shaz
CWConnie M. Westhoff
Connie M. Westhoff

7 November 2024 in Blood
Verified
Journal Article
Closed access
SCStella T. Chou
Stella T. Chou
JMJulia Mewha
Julia Mewha
DFDavid F. Friedman
David F. Friedman
VLVictoria Lazariu
Victoria Lazariu
SMShaimaa Makrm
Shaimaa Makrm
CWConnie M. Westhoff
Connie M. Westhoff
Anti-D can occur in D-positive patients who inherit RHD genetic variants encoding partial D antigen expression, but unexpected anti-D is also found in the plasma of patients with sickle cell disease who have conventional RHD gene(s) and are transfused with units from Black donors. These anti-D are likely stimulated by variant Rh expressed on donor cells; however, patients with anti-D, regardless of cause, are transfused for a lifetime with D-negative (Rh-negative) blood. This results in significant increased use of Rh-negative units, especially for those requiring chronic transfusion, which can strain Rh-negative blood inventories. We tested whether D-positive patients who made anti-D and had conventional RhD by RHD genotyping could safely be returned to D-positive transfusions without anti-D reappearance or compromised red blood cell survival using RHD genotype-matched units from Black donors. Five patients receiving chronic red cell exchange received an increasing number of D-positive units per procedure with a total of 72 D-positive RHD genotyped units transfused, with no anti-D restimulation. Unexpected anti-C and anti-E were identified during the study associated with donors with variant RHCE alleles. RH genotyping of D-positive units for transfusion may improve use and allocation of valuable Black donor units and reduce demand for Rh-negative blood. This trial was registered at www.clinicaltrials.gov as NCT04156906.